Cancer Imaging and Radiobiology (CIR) The goal of the Cancer Imaging & Radiobiology (CIR) Program is to realize technology innovations that promote, foster and underpin translational research in the detection, diagnosis, treatment and therapeutic monitoring of solid cancers and human health status following radiation exposure. The group utilizes biophysical and engineering approaches and methods to develop and improve imaging, measurement, and treatment technologies that aid in understanding the biological and physiological processes that are indicators of the growth, progression and regression of cancer in diagnostic and therapeutic settings. CIR members seek to achieve these goals by conducting research addressing 3 themes: (1) Cancer Nanotechnology to deliver and excite targeted magnetic nanoparticles for treatment of loco-regional and potentially metastatic cancers, (2) Electron paramagnetic resonance (EPR) in Radiation Dosimetry to quantitate radiation exposure, and (3) Imaging and Image-Guidance in Cancer Investigations to develop molecular and physically-based imaging and image-guided techniques for cancer detection, characterization and surgery or other interventions. CIR has 22 members from 10 departments holding $17.8M in peer-reviewed funding (total costs, with $4.0M from NCI, 25%) which includes multi-project support for the Dartmouth Center for Cancer Nanotechnology Excellence (U54-CA151662), the Dartmouth Physically-Based Biodosimetry Center for Medical Countermeasures against Radiation (U19AI091173), and the Center for Surgical Innovation for Translational Research at Dartmouth (C06- RR030432). CIR's publication record over the previous 5-year funding period exceeds 317 cancer-related contributions to the peer-reviewed literature (10% [31] in leading journals), with intra- and inter-programmatic publication rates of 60% (189) and 20% (64), respectively. All 22 members are co-authors on intra-programmatic publications, and 20 are co-authors on inter-programmatic. These data are indicative of an innovative, productive, and highly interactive cancer-focused program. During the current funding period, CIR members have been responsible for publishing the first evidence that (i) passive bioelectrical properties discriminate high and low-grade prostate adenocarcinoma, (ii) breast tumor response to neoadjuvant chemotherapy can be determined within the first 4 weeks of initiation of treatment with diffuse near-infrared spectral tomography, (iii) ALA-induced PpIX accumulates with diagnostically-significant levels of fluorescence in low-grade glioma, (iv) multiple nanoparticle bound states can be concurrently quantified with Magnetic Particle Imaging of Brownian motion, (v) dual tracer fluorescence spectroscopy enables quantitative molecular imaging of tumor receptor binding of targeted diagnostic and therapeutic agents, (vi) finger and toenails can be used as practical individualized radiation dosimeters, and (vii) Cherenkov radiation dose can be measured in breast cancer patients via fluorescence imaging. CIR provides an innovative framework, facilitated through NCCC support, for investigating new approaches to identify and manage cancer in patients and radiation exposure in survivors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Shee, Kevin; Jiang, Amanda; Varn, Frederick S et al. (2018) Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer. FASEB J :fj201801241R
Rodriguez-Garcia, Marta; Fortier, Jared M; Barr, Fiona D et al. (2018) Aging impacts CD103+ CD8+ T cell presence and induction by dendritic cells in the genital tract. Aging Cell 17:e12733
Shajani-Yi, Zahra; de Abreu, Francine B; Peterson, Jason D et al. (2018) Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia 20:256-262
Szczepiorkowski, Zbigniew M; Burnett, Christine A; Dumont, Larry J et al. (2018) Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion 58:943-950
Bossé, Yohan; Amos, Christopher I (2018) A Decade of GWAS Results in Lung Cancer. Cancer Epidemiol Biomarkers Prev 27:363-379
Pande, Mala; Joon, Aron; Brewster, Abenaa M et al. (2018) Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One 13:e0196245
Smith, T Jarrod; Sondermann, Holger; O'Toole, George A (2018) Co-opting the Lap System of Pseudomonas fluorescens To Reversibly Customize Bacterial Cell Surfaces. ACS Synth Biol 7:2612-2617
Gorlova, Olga Y; Li, Yafang; Gorlov, Ivan et al. (2018) Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One 13:e0189498
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Cai, Yunliang; Wu, Shaoju; Zhao, Wei et al. (2018) Concussion classification via deep learning using whole-brain white matter fiber strains. PLoS One 13:e0197992

Showing the most recent 10 out of 1911 publications